Search Results 191-200 of 11512 for Cirrhosis

  1. A Study Of Glecaprevir (GLE)/Pibrentasvir (PIB) In Treatment-Naïve Adults With Chronic Hepatitis C Virus (HCV) Genotype 1, 2, 4, 5 Or 6 Infection And Compensated Cirrhosis - Mayo Clinic

    ... Cirrhosis. Print details. Share; Facebook · Twitter. Overview; Participation eligibility; Participating Mayo Clinic info; More information. Overview. Tab Title ...

  2. A Study Of OCE-205 In Participants With Cirrhosis With Ascites Who Developed Hepatorenal Syndrome-Acute Kidney Injury - Mayo Clinic

    OCE-205 is being tested to treat participants who have developed Hepatorenal Syndrome-Acute Kidney Injury as a complication of cirrhosis with ascites.

  3. Primary Biliary Cholangitis (PBC) Clinical Trials - Mayo Clinic Research

    Primary Biliary Cirrhosis (PBC) is a serious, life--threatening, bile acid related liver disease of unknown cause. Without treatment, it frequently progresses ...

  4. Safety And Efficacy Of Simtuzumab (GS-6624) In Adults With Advanced Liver Fibrosis But Not Cirrhosis Secondary To Non-Alcoholic Steatohepatitis (NASH) - Mayo Clinic

    Safety And Efficacy Of Simtuzumab (GS-6624) In Adults With Advanced Liver Fibrosis But Not Cirrhosis Secondary To Non-Alcoholic Steatohepatitis (NASH).

  5. MELD Score and 90-Day Mortality Rate for Alcoholic Hepatitis - Medical Professionals - Mayo Clinic

    This calculator is intended for use by health care providers. The results should not be used alone to determine medical treatment. This tool is a statistical ...

  6. Mayo Clinic Q and A: Medication may help slow progression of PBC

    DEAR MAYO CLINIC: I was diagnosed with primary biliary cirrhosis three months ago. I don't have any symptoms yet but wonder what I should look for.

  7. International Registry of Acute Kidney Injury in Cirrhosis: The GLOBAL AKI Project - Mayo Clinic

    The purpose of this study is to identify the clinical characteristics, the management and the outcomes of acute kidney injury (AKI) in patients with cirrhosis ...

  8. Emricasan, An Oral Caspase Inhibitor, In Subjects With Non-Alcoholic Steatohepatitis (NASH) Cirrhosis And Severe Portal Hypertension - Mayo Clinic

    This is a multicenter, randomized, double-blind, placebo-controlled trial involving subjects with NASH cirrhosis and severe portal hypertension (defined as HVPG ...

  9. Hepatic Encephalopathy Clinical Trials

    Hepatic encephalopathy (HE) is a serious complication of cirrhotic stage liver disease. It is reported that 30-70% of all patients with cirrhosis have HE. The ...

  10. Research - Mayo Clinic Research

    Alcoholic liver disease is a significant cause of liver cirrhosis and a major contributor to global liver-related mortality. Our program examines various ...